Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 550Specimen Handling 462Carboplatin 441Magnetic Resonance Spectroscopy 429Cyclophosphamide 412Cisplatin 398Radiotherapy 313Gemcitabine 310Bevacizumab 306Paclitaxel 294Biopsy 259Drug Therapy 248Capecitabine 241Oxaliplatin 239fludarabine 238Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 202Dexamethasone 186Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 145durvalumab 143Leucovorin 138atezolizumab 137toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Trabedersen × Clear all
NCT06579196 2025-07-24

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

University of Nebraska

Phase 1/2 Recruiting
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡